2026 Elizabeth R. Plimack: Medicine Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Medicine	83	15339	14424	7735	7152	652	52539

Overview

Elizabeth R. Plimack is affiliated with the Fox Chase Cancer Center in the United States. Their research spans the field of Medicine, with a significant focus on Surgery, Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, and Cancer Research. The predominant areas of study include Bladder and Urothelial Cancer Treatments, Renal cell carcinoma treatment, Cancer Immunotherapy and Biomarkers, Urinary and Genital Oncology Studies, Renal and related cancers, Economic and Financial Impacts of Cancer, and Cancer Genomics and Diagnostics.

Among the notable recent papers associated with Elizabeth R. Plimack are:

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial, 2020, The Lancet Oncology
Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology, 2020, Journal of the National Comprehensive Cancer Network
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology, 2022, Journal of the National Comprehensive Cancer Network
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial, 2020, ESMO Open
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial, 2020, Cancer

Elizabeth R. Plimack has frequently collaborated with several coauthors, including:

Brian I. Rini
Toni K. Choueiri
David F. McDermott
Daniel M. Geynisman
Hans J. Hammers

Their work has been regularly published in leading academic journals, notably:

Journal of Clinical Oncology
Cancer
European Urology
Annals of Oncology
European Urology Oncology

Elizabeth R. Plimack's contributions cover a wide spectrum of oncology research, especially focusing on cancer immunotherapy, renal cancers, and treatment guidelines. Their publications reflect involvement in significant clinical trials and guideline development pertinent to bladder and kidney cancers.

Best Publications

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Robert J. Motzer;Bernard Escudier;David F. McDermott;Saby George

5870
Citations
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Robert J Motzer;Nizar M Tannir;David F McDermott;Osvaldo Arén Frontera

4684
Citations
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Brian I. Rini;Elizabeth R. Plimack;Viktor Stus;Rustem Gafanov

3343
Citations
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

Razvan Cristescu;Robin Mogg;Mark Ayers;Andrew Albright

2227
Citations
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

Padmanee Sharma;Margitta M. Retz;Arlene Siefker-Radtke;Ari D. Baron

1702
Citations
Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy

Woonyoung Choi;Sima Porten;Seungchan Kim;Daniel Willis

1644
Citations
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

Arjun V Balar;Daniel Castellano;Peter H O'Donnell;Petros Grivas

1388
Citations
Prostate cancer. Clinical practice guidelines in oncology.

James Mohler;Robert R. Bahnson;Barry Boston;J. Erik Busby

1318
Citations
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

James L. Mohler;Emmanuel S. Antonarakis;Andrew J. Armstrong;Anthony V. D'Amico

1298
Citations
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

Robert J. Motzer;Brian I. Rini;David F. McDermott;Bruce G. Redman

1152
Citations
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

Christos E. Kyriakopoulos;Yu Hui Chen;Michael A. Carducci;Glenn Liu

970
Citations
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

Robert J. Motzer;Brian I. Rini;David F. McDermott;Osvaldo Arén Frontera

799
Citations
Prostate Cancer, Version 1.2016

James L. Mohler;Andrew J. Armstrong;Robert R. Bahnson;Anthony Victor D'Amico

720
Citations
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

Thomas Powles;Elizabeth R Plimack;Denis Soulières;Tom Waddell

613
Citations
Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

Robert J Motzer;Eric Jonasch;Neeraj Agarwal;Sam Bhayani

533
Citations
Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer

Elizabeth R. Plimack;Roland L. Dunbrack;Timothy A. Brennan;Mark D. Andrake

480
Citations
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.

Laurence Albiges;Nizar M. Tannir;Mauricio Burotto;David McDermott;David McDermott

458
Citations
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study

Hans J. Hammers;Elizabeth R. Plimack;Jeffrey R. Infante;Brian I. Rini

448
Citations
Prostate Cancer,,Version 2.2014 Clinical Practice Guidelines in Oncology

James L. Mohler;Philip W. Kantoff;Andrew J. Armstrong;Robert R. Bahnson

435
Citations
Bladder cancer. Clinical practice guidelines in oncology.

Peter E. Clark;Neeraj Agarwal;Matthew C. Biagioli;Mario A. Eisenberger

413
Citations

Frequent Co-Authors

David F. McDermott Beth Israel Deaconess Medical Center

Brian I. Rini Vanderbilt University Medical Center

Thomas Powles Queen Mary University of London

Robert G. Uzzo Fox Chase Cancer Center

Joaquim Bellmunt Beth Israel Deaconess Medical Center

Toni K. Choueiri Harvard University

Robert J. Motzer Memorial Sloan Kettering Cancer Center

Jonathan E. Rosenberg Memorial Sloan Kettering Cancer Center

Ulka N. Vaishampayan University of Michigan–Ann Arbor

Dean F. Bajorin Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Related Online Degrees & Career Pathways

If you're interested in healthcare beyond traditional medical school, there are a variety of affordable and flexible online degree options to consider. These programs can lead to diverse career paths in healthcare leadership, advanced practice, and pharmacy—each offering unique benefits for students with different professional goals.

For those who want to lead healthcare organizations or move into administrative roles, many universities offer some of the best online mha programs. These Master of Healthcare Administration (MHA) degrees emphasize leadership, health policy, and management skills. If affordability is a top priority, explore the cheapest online mha options to minimize tuition without compromising quality.

For nurses seeking to become nurse practitioners or move into advanced clinical roles, the cheapest dnp programs online are tailored for working professionals and help students advance their practice while allowing them to balance their careers and studies.

Interested in pharmacy or pharmaceutical research? There are pathways to earn a pharmacy degree online, equipping you with essential knowledge in drug therapy and patient safety.

No matter your goals, these online healthcare degrees provide both affordability and flexibility—key factors when planning your career in medicine and health sciences.